New York City-based Pfizer and Russia-based NovaMedica completed a long-term strategic partnership to transfer the rights and technologies for the production of more than 30 drugs from Pfizer's to NovaMedica's portfolio.
Under the partnership's terms, Pfizer will invest in NovaMedica and the companies will construct a manufacturing facility in the Russian province of Kaluga, with construction set to begin mid-2017. The facility may be used to manufacture products for export markets, according to NovaMedica.
NovaMedica will manufacture the more than 30 sterile injectable products transferred from Pfizer at the Kaluga facility. The products include treatments for severe bacterial and fungal infections, cardiovascular disease, inflammatory diseases and cancer.
The partnership was announced in July 2016.
More articles on supply chain:
Ex-Turing CEO Martin Shkreli: US healthcare costs are up because of physicians, not drug prices
FDA approves first drug for rare spinal disease
FDA imposes clinical hold on Seattle Genetics' cancer drug after 4 deaths